Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration

British Journal of Ophthalmology

Volumn 99, Issue 2, 2015, Pages 220-226

  Holz, Frank G ^a   Tadayoni, Ramin ^b   Beatty, Stephen ^c   Berger, Alan ^d   Cereda, Matteo G ^e   Cortez, Rafael ^f   Hoyng, Carel B ^g   Hykin, Philip ^h   Staurenghi, Giovanni ^e   Heldner, Stephanie ⁱ   Bogumil, Timon ^j   Heah, Theresa ^j   Sivaprasad, Sobha ^h,k  

^a UNIVERSITY OF BONN   (Germany)

^b HÔPITAL LARIBOISIÈRE   (France)

^c Institute of Eye Surgery   (Ireland)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF MILAN   (Italy)

^f Centro de Cirugia Oftalmologica CECOF   (Venezuela)

^g RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^h MOORFIELDS EYE HOSPITAL   (United Kingdom)

ⁱ BAYER PHARMA AG   (Germany)

^j BAYER CORPORATION   (United States)

^k KING S COLLEGE HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

AGE RELATED MACULAR DEGENERATION; AGED; ARTICLE; CANADA; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; FRANCE; GERMANY; HUMAN; IRELAND; ITALY; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; OBSERVATIONAL STUDY; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PATIENT MONITORING; RETROSPECTIVE STUDY; UNITED KINGDOM; VENEZUELA; VISUAL ACUITY; WET MACULAR DEGENERATION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; EUROPE; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOPHYSIOLOGY; PHYSIOLOGY; RETREATMENT; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CANADA; EUROPE; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; RANIBIZUMAB; RETREATMENT; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENEZUELA; VISUAL ACUITY; WET MACULAR DEGENERATION;

EID: 84921495108     PISSN: 00071161     EISSN: 14682079     Source Type: Journal    
DOI: 10.1136/bjophthalmol-2014-305327     Document Type: Article

References (20)

1. Ambati J, Fowler BJ. Mechanisms of age-related macular degeneration. Neuron 2012;75:26-39.
2. Slakter JS, Stur M. Quality of life in patients with age-related macular degeneration: impact of the condition and benefits of treatment. Surv Ophthalmol 2005;50:263-73.
3. Brown DM, Kaiser PK, Michels M, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006;355:1432-44.
4. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31.
5. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150:315-24.
6. Schmidt-Erfurth U, Eldem B, Guymer R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 2011;118:831-9.
7. Martin DF, Maguire MG, Fine SL, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012;119:1388-98.
8. Busbee BG, Ho AC, Brown DM, et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013;120:1046-56.
9. Chakravarthy U, Harding SP, Rogers CA, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411.
10. Holz FG, Amoaku W, Donate J, et al. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study. Ophthalmology 2011;118:663-71.
11. Gupta OP, Shienbaum G, Patel AH, et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. Ophthalmology 2010;117:2134-40.
12. Toalster N, Russell M, Ng P. A 12-month prospective trial of inject and extend regimen for ranibizumab treatment of age-related macular degeneration. Retina 2013;33:1351-8.
13. Lucentis [summary of product characteristics]. Huningue, France: Novartis Pharma S.A.S., 2013.
14. TM (ranibizumab injection). Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda-docs/label/2013/125156s081lbl.pdf (accessed 13 Sep 2013).
15. Cohen SY, Mimoun G, Oubraham H, et al. Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE Study. Retina 2013;33:474-81.
16. Cohen SY, Dubois L, Tadayoni R, et al. Results of one-year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol 2009;148:409-13.
17. Finger RP, Wiedemann P, Blumhagen F, et al. Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 2013;91:540-6.
18. Finger RP, Holz FG. Access to healthcare services for elderly patients with neovascular age-related macular degeneration. Ophthalmologe 2012;109:474-8.
19. Rotsos T, Patel PJ, Chen FK, et al. Initial clinical experience of ranibizumab therapy for neovascular age-related macular degeneration. Clin Ophthalmol 2010;4:1271-5.
20. Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumabtreated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 2013;120:2292-9.